Mycobacterium chelonae Infection Management

Introduction to Mycobacterium chelonae

Mycobacterium chelonae is a rapidly growing nontuberculous mycobacterium that primarily causes skin, bone, and soft tissue infections, with treatment being substantially easier than its close relative M. abscessus 1
M. chelonae is a ubiquitous environmental organism found in water and soil that enters through direct inoculation via trauma, surgery, or contaminated medical procedures 1
Rapid growth distinguishes it from slow-growing mycobacteria, allowing culture identification within days rather than weeks 1
It is critical to differentiate M. chelonae from M. abscessus since therapy for M. chelonae is potentially easier 1

Skin, bone, and soft tissue disease are the most important clinical manifestations of M. chelonae infection 1
Localized infections at puncture wound sites, surgical sites, or traumatic injuries are common presentations 2
M. chelonae is the most frequently reported etiologic agent in LASIK-associated keratitis 1
Tissue biopsy is the most sensitive means of obtaining specimens for culture 1
Only 50-82% of excised nodes yield positive cultures even with compatible histopathology 1

M. chelonae demonstrates predictable susceptibility patterns that guide treatment selection 1
Tobramycin has 100% susceptibility, making it a preferred agent 1
Clarithromycin has 100% susceptibility 1
Linezolid has 90% susceptibility 1
Imipenem has 60% susceptibility, making it a preferred agent over cefoxitin 1
Amikacin has 50% susceptibility 1
Doxycycline has only 25% susceptibility 1, 4
Ciprofloxacin has 20% susceptibility 1

For uncomplicated skin disease, clarithromycin monotherapy at 500 mg twice daily for 6 months achieved cure in 92% of patients 1
A minimum of 4 months of combination drug therapy is necessary to provide a high likelihood of cure and minimize macrolide resistance risk 1, 4
Initial combination therapy with clarithromycin plus a second agent based on susceptibility (tobramycin or imipenem preferred) is recommended 1, 4
For bone infections, 6 months of therapy is recommended 1
Surgery is generally indicated with extensive disease, abscess formation, or where drug therapy is difficult 1, 4
Removal of foreign bodies (breast implants, catheters) is important or essential to recovery 1
Complete surgical excision of affected tissue combined with optimized antimicrobial therapy is the treatment of choice for treatment failure or persistent infection 4

Monotherapy risks macrolide resistance development; combination therapy should be used initially for serious infections 1, 4
Inadequate drug penetration into lymph nodes may contribute to treatment failure 4
Long-term follow-up is essential to ensure complete eradication 3
Doxycycline has only 25% susceptibility and may explain treatment failures when used 4